3023869-94-2
Chemical Structure
FAPI-mFS
- CAS No.: 3023869-94-2
- Formula:C53H69F3N12O15S
- Molecular Weight:1203.25
InChIKey: RMDGGTNSHBGXHW-PIFWXFIOSA-N
SMILES: O=C(N[C@H](C(N1CCN(CCCOC2=CC=C(N=CC=C3C(NCC(N4[C@H](C#N)CC(F)(F)C4)=O)=O)C3=C2)CC1)=O)CCCCNC(C5=CC(OS(F)(=O)=O)=CC=C5)=O)CN6CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC6
Biological Activity: FAPI-mFS is a selective fibroblast activation protein (FAP) inhibitor with an IC50 of 0.0014 μM against human FAP. Through its covalent binding property with FAP, FAPI-mFS enhances its uptake and retention time in cancer cells. When radiolabeled with 68Ga, FAPI-mFS serves as a PET/CT imaging agent with superior tumor-to-background tissue contrast and lesion detection capability. When radiolabeled with 177Lu or 225Ac, FAPI-mFS induces tumor regression and inhibition in preclinical models. FAPI-mFS can be used in studies related to cancer and radionuclide-conjugated drugs (RDC)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FAPI-mFS | 98.71% | FAPI-mFS is a selective fibroblast activation protein (FAP) inhibitor with an IC50 of 0.0014 μM against human FAP. Through its covalent binding property with FAP, FAPI-mFS enhances its uptake and retention time in cancer cells. When radiolabeled with 68Ga, FAPI-mFS serves as a PET/CT imaging agent with superior tumor-to-background tissue contrast and lesion detection capability. When radiolabeled with 177Lu or 225Ac, FAPI-mFS induces tumor regression and inhibition in preclinical models. FAPI-mFS can be used in studies related to cancer and radionuclide-conjugated drugs (RDC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Cui XY, et al. Covalent targeted radioligands potentiate radionuclide therapy. Nature. 2024 Jun;630(8015):206-213. [Content Brief]
- [2]. Luo Y, et al. Based on small molecules: development and application of fibroblast activation protein inhibitors radiopharmaceutical in tumor precision therapy. Frontiers in pharmacology. 2025;16:1593380. [Content Brief]
